In this webinar we will discuss the new and encouraging developments in understanding and treating myelodysplastic syndromes. We will discuss new information about why people develop myelodysplastic syndromes, and the evolving role genetic testing is playing in understanding this. We will outline the many novel therapies that are on the horizon for myelodysplastic syndromes, including targeted and immunotherapies, and how these are poised to improve both quality of life and outcomes for patients. We will aim to put this information into the Canadian context, and highlight the exciting and innovative research being carried out across the country with the support of organizations like the Leukemia Lymphoma Society of Canada. The goal of this webinar is to empower patients with information about myelodysplastic syndromes and outline the future treatment landscape.
Dr. Ryan Stubbins, MD, MSc, FRCPC
Research Fellow, Genome Sciences Centre, BC Cancer
Clinical Fellow, Leukemia/BMT Program of BC, BC Cancer
Leukemia/Lymphoma Society of Canada Clinician Scientist Scholarship Recipient
Dr. Ryan Stubbins is currently a fellow at the BC Cancer Genome Sciences Centre and the Leukemia/BMT Program of BC. His clinical and research interests are focused on the myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia. He completed his medical training at the University of Saskatchewan and the University of Alberta, where he also completed a Master of Science in Translational Medicine. He subsequently completed his Clinical Hematology training at the University of British Columbia. He was awarded the Leukemia/Lymphoma Society of Canada Clinician-Scientist award to investigate precision medicine approaches to epigenetic therapies in myeloid malignancies.